caa a22 4500 445882638 CHVBK 20180317145548.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1007/s10157-011-0518-x doi (NATIONALLICENCE)springer-10.1007/s10157-011-0518-x Long-term complete response to very-low-dose interleukin-2 therapy in patients with metastatic renal cell carcinoma: report of two cases [Elektronische Daten] [Ken-ichi Harada, Hideaki Miyake, Toshifumi Kurahashi, Masato Fujisawa] Before the advent of molecular-targeted agents, immunotherapy using cytokines, such as interferon-α (IFN-α) and interleukin-2 (IL-2), had been the mainstay of treatment for patients with metastatic renal cell carcinoma (mRCC), and this therapy may still be occasionally recommended for such patients. In this report, we present two cases of mRCC who were treated with very-low-dose IL-2 therapy and subsequently achieved complete response (CR). Both cases received adjuvant IFN-α therapy following radical nephrectomy; however, multiple lung metastases developed 4 and 12months after surgery, and low-dose IL-2 (0.7million U/day) was then administered twice per week for 14 and 35months, respectively. In both cases, metastatic lesions completely regressed 3 and 20months after the start of IL-2 therapy, and these responses have persisted for 81 and 67months, respectively, to date. These findings suggest that immunotherapy with IL-2, even at a very-low-dose setting, may achieve the induction of CR in mRCC; accordingly, IL-2-based immunotherapy should be considered as the initial treatment for appropriately selected patients with mRCC. Japanese Society of Nephrology, 2011 Renal cell carcinoma nationallicence Interleukin-2 nationallicence Metastasis nationallicence Complete response nationallicence Harada Ken-ichi Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, 650-0017, Kobe, Japan aut Miyake Hideaki Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, 650-0017, Kobe, Japan aut Kurahashi Toshifumi Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, 650-0017, Kobe, Japan aut Fujisawa Masato Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, 650-0017, Kobe, Japan aut Clinical and Experimental Nephrology Springer Japan 15/6(2011-12-01), 966-969 1342-1751 15:6<966 2011 15 10157 https://doi.org/10.1007/s10157-011-0518-x text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10157-011-0518-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Harada Ken-ichi Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, 650-0017, Kobe, Japan aut NATIONALLICENCE 700 1- Miyake Hideaki Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, 650-0017, Kobe, Japan aut NATIONALLICENCE 700 1- Kurahashi Toshifumi Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, 650-0017, Kobe, Japan aut NATIONALLICENCE 700 1- Fujisawa Masato Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, 650-0017, Kobe, Japan aut NATIONALLICENCE 773 0- Clinical and Experimental Nephrology Springer Japan 15/6(2011-12-01), 966-969 1342-1751 15:6<966 2011 15 10157 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer